While an offer is an important part of the negotiation process, it is only the first step. The government sent price justifications to companies along with offers. However, H.H.S. Details not disclosed Until a final offer is agreed by September.
PhRMA, the industry’s powerful lobby group, said: The public will have no information to understand how the Centers for Medicare and Medicaid Services works. weighted elements or evaluation of the therapeutic value of the product leading to the starting price.
Administration officials said they would welcome drug companies to make their offers public, but said it was unlikely to happen. The federal government and manufacturers 3 meetings From now until negotiations are scheduled ends in august.
“This is a big step, and it’s been a long time coming. With Medicare’s actions and negotiations with all 10 companies, we are well on our way to lowering costs,” said Neera Tanden, White House Domestic Policy Advisor. He said this at a press conference on Wednesday.
Companies are also working on active litigation against the administration. Until these cases play out, it’s unclear whether the bargaining program will even survive, although judges in previous cases appear skeptical of the industry’s claims.
For a long time, the industry has been negotiating Stifling private innovation It prevents companies from bringing new drugs to market.
But the policy is clear, and the White House and Department of Health and Human Services are vocally promoting this effort.
“Medicare will no longer accept the prices drug companies are demanding for these drugs,” President Biden said in a statement.
